Literature DB >> 18671217

Discovery of novel non-cyclam polynitrogenated CXCR4 coreceptor inhibitors.

Sofia Pettersson1, Violeta I Pérez-Nueno, Laia Ros-Blanco, Raimon Puig de La Bellacasa, María Obdulia Rabal, Xavier Batllori, Bonaventura Clotet, Imma Clotet-Codina, Mercedes Armand-Ugón, José Esté, José I Borrell, Jordi Teixidó.   

Abstract

HIV cell fusion and entry have been validated as targets for therapeutic intervention against infection. Bicyclams were the first low-molecular-weight compounds to show specific interaction with CXCR4. The most potent bicyclam was AMD3100, in which the two cyclam moieties are tethered by a 1,4-phenylenebis(methylene) bridge. It was withdrawn from clinical trials owing to its lack of oral bioavailability and cardiotoxicity. We have designed a combinatorial library of non-cyclam polynitrogenated compounds by preserving the main features of AMD3100. At least two nitrogen atoms on each side of the p-phenylene moiety, one in the benzylic position and the other(s) in the heterocyclic system were maintained, and the distances between them were similar to the nitrogen atom distances in cyclam. A selection of diverse compounds from this library were prepared, and their in vitro activity was tested in cell cultures against HIV strains. This led to the identification of novel potent CXCR4 coreceptor inhibitors without cytotoxicity at the tested concentrations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18671217     DOI: 10.1002/cmdc.200800145

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  6 in total

1.  Ligand-guided optimization of CXCR4 homology models for virtual screening using a multiple chemotype approach.

Authors:  Marco A C Neves; Sérgio Simões; M Luisa Sá e Melo
Journal:  J Comput Aided Mol Des       Date:  2010-10-20       Impact factor: 3.686

2.  Computational analysis of the structural mechanism of inhibition of chemokine receptor CXCR4 by small molecule antagonists.

Authors:  Sameer P Kawatkar; Maocai Yan; Harsukh Gevariya; Mi Youn Lim; Steven Eisold; Xuejun Zhu; Ziwei Huang; Jing An
Journal:  Exp Biol Med (Maywood)       Date:  2011-06-22

3.  Bioluminescent CXCL12 fusion protein for cellular studies of CXCR4 and CXCR7.

Authors:  Kathryn Luker; Mudit Gupta; Gary Luker
Journal:  Biotechniques       Date:  2009-07       Impact factor: 1.993

Review 4.  Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection.

Authors:  Jian J Tan; Xiao J Cong; Li M Hu; Cun X Wang; Lee Jia; Xing-Jie Liang
Journal:  Drug Discov Today       Date:  2010-01-22       Impact factor: 7.851

5.  The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma.

Authors:  Giovanni Luca Gravina; Andrea Mancini; Francesco Marampon; Alessandro Colapietro; Simona Delle Monache; Roberta Sferra; Flora Vitale; Peter J Richardson; Lee Patient; Stephen Burbidge; Claudio Festuccia
Journal:  J Hematol Oncol       Date:  2017-01-05       Impact factor: 17.388

6.  Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma.

Authors:  Clara Recasens-Zorzo; Teresa Cardesa-Salzmann; Paolo Petazzi; Laia Ros-Blanco; Anna Esteve-Arenys; Guillem Clot; Martina Guerrero-Hernández; Vanina Rodríguez; Davide Soldini; Alexandra Valera; Alexandra Moros; Fina Climent; Eva González-Barca; Santiago Mercadal; Leonor Arenillas; Xavier Calvo; José Luís Mate; Gonzalo Gutiérrez-García; Isolda Casanova; Ramón Mangues; Alejandra Sanjuan-Pla; Clara Bueno; Pablo Menéndez; Antonio Martínez; Dolors Colomer; Roger Estrada Tejedor; Jordi Teixidó; Elias Campo; Armando López-Guillermo; José Ignacio Borrell; Luis Colomo; Patricia Pérez-Galán; Gaël Roué
Journal:  Haematologica       Date:  2018-06-28       Impact factor: 9.941

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.